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A PROSPECTIVE STUDY OF NEONATAL WITHDRAWAL IN INFANTS EXPOSED TO
COCAINE AND METHADONE. Barbara A. McGee and Linda C. Mayes. Child Study Center,

Yale University School of Medicine, New Haven, CT.

The purpose of the present study was to prospectively examine the following hypothesis: Cocaine
use among pregnant women maintained on methadone increases the duration and the severity of
the neonatal abstinence syndrome (NAS) among their infants. A group of 23 infants born to
mothers participating in a methadone maintenance program were followed for severity of NAS
after poly-drug exposure in utero. Severity of withdrawal was indexed by infant length of stay in
the hospital, duration of treatment with medication, first and maximum symptom scores, and the
dosages of withdrawal medications used. During pregnancy, information was gathered on
maternal daily methadone dose, urine toxicology, pregnancy complications, and medication use.
Fourteen (61%) of the mothers in the sample had positive urine screens for cocaine, and five
(22%) took benzodiazepines regularly during pregnancy. Infants exposed to both cocaine and
methadone trended toward a shorter duration of therapy, however, the differences were not found
to be statistically significant (F = 1.54 , p = .23). There was a positive correlation between
maternal methadone dose and the number of days infants spent on the highest doses of
withdrawal medication (r = .53, p < .01). In addition, benzodiazepine exposure significantly
contributed to longer infant hospital stays (F = 8.3, p < .01), and duration of medication treatment
(F = 10.37, p < .01). These findings suggest that the effect of cocaine on withdrawal from
methadone in infants is small, having either no contributory effect or only a mild degree of
shortening of the duration of withdrawal symptoms.
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1
INTRODUCTION
Substance abuse in pregnancy
More than 100,000 babies born in the United States annually are believed to have

been exposed to cocaine or other drugs during the critical period of fetal brain

development.1 The National Institute on Drug Abuse reports 70 to 90% of Americans

between the ages of 15 to 40 years have used mood-altering chemicals, approximately half

of whom are women with reproductive potential.2 Among women in this group,

approximately 60% drink alcohol, 32% smoke nicotine cigarettes, and 11% use marijuana.

Some reports suggest a leveling off of overall cocaine use in this country over the last five

years.3 However, young women continue to be the fastest growing group of cocaine users,

with some cities reporting a 12 to 15% increase in cocaine use among women since 1991.

In a population of women presenting for prenatal care, screening a single urine sample for

alcohol, cannabinoids, cocaine, and opiates reveals positive urine toxicology results in 3 to

50% of cases, depending on the methods and populations studied.4'6

A 1988 study,2 conducted by the National Association of Perinatal Addiction

Research and Education, and involving approximately 155,000 pregnancies annually from

36 hospitals around the country, found that 11% of the mothers used at least one of the

following: heroin, methadone, marijuana, PCP, amphetamines, and most commonly

cocaine. A later study of infants born to substance abusing mothers in New York City

revealed the changing patterns of drug exposure through the 1980's.7 Initially, heroin and
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methadone use during pregnancy predominated. As crack became more readily available,

the trend began to shift toward increasing cocaine use in pregnancy, with frequency of

cocaine use being reported on birth certificates 2.3 times more frequently than heroin and

methadone combined. Frequently, more than one drug is being abused during pregnancy.

Among women maintained on methadone for opiate addiction, concomitant, regular use of

cocaine or crack has been reported in 20 to 60%.8,9

The increase in cocaine use among women of reproductive age has caused concern

about the potential maternal and fetal effects of illicit drug abuse during pregnancy.

Pregnancy in women who use illegal drugs or alcohol is, by definition, a high risk. In

untreated women who use cocaine during pregnancy, serious complications have been

reported, such as maternal deaths, myocardial infarction, cerebrovascular accidents, and

abruptio placentae.10'18 A correlation exists between substance abuse in pregnancy and a

higher exposure to sexually transmitted diseases, systemic infections including HIV, poor

nutrition, decreased use of health services, and indiscriminate sexual activity.1213,19 -21

These factors, as well as the chaotic lifestyle that accompanies substance abuse,22 creates

a high-risk environment for fetal development, warranting concern about the outcome of

infants exposed to drugs

in utero.
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Neonatal abstinence syndrome
One clear outcome of substance abuse in pregnancy is exhibited by the neonatal

withdrawal syndrome experienced by infants born to opiate-addicted mothers. Newborns

who have been exposed prenatally to heroin or methadone are born passively addicted to

the drug and exhibit withdrawal symptoms in the first days to weeks after delivery.23"25

Heroin and methadone are easily transferred across the placenta, and have been found to

accumulate in fetal tissues and fluids when exposure occurs during gestation.26 27 Neonatal

Abstinence Syndrome (NAS) results when the placental transfer of opiates to the infant is

disrupted by delivery. The majority of infants bom to opiate-addicted women experience

NAS,28 which is characterized by signs and symptoms of central nervous system

hyperirritability, gastrointestinal dysfunction, respiratory distress, poor sucking reflex,

tremors, hypertonicity, and high pitched crying (Figure 1). The majority of symptoms appear

within 72 hours of delivery.29 Several types of clinical courses have been described in the

literature on NAS.29 Withdrawal has been noted to be mild and brief, be delayed in onset,

have a step-wise increase in severity, or have a biphasic course. More severe withdrawal

tends to occur in infants whose mothers have taken large amounts of drugs for a long

time.30 31 In general, the closer to delivery a mother takes heroin, the greater the delay in

onset of withdrawal and the more severe the symptoms in her baby. Duration of symptoms

can extend from six days to twelve weeks depending on the extent of drug exposure, as

well as concomitant medical problems of the infant. During the later weeks of withdrawal,
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infants may have hyperphagia, increased sucking, sweating, irregular sleep patterns, loose

stools, and poor tolerance to holding or to abrupt changes of position and space.29

The severity of withdrawal in an infant exposed to opiates

in utero is generally

monitored by following specific symptoms with a standardized scoring system. An early

scoring system was proposed by Lipsitz32 to quantitate the clinical symptoms of abstinence.

The degree of tremor, irritability, and gastrointestinal symptoms were scored from zero to

three, based on observer judgement. The presence or absence of tachypnea, sneezing,

yawning, vomiting, and fever were noted and scored as either zero or one. A cumulative

withdrawal score was then calculated and the assessment could be repeated at a standard

frequency during the infant hospital stay. In this way, infants were compared to each other

and the progression of withdrawal severity was monitored in individual infants. A more

detailed system of scoring was developed and standardized by Finnegan,33 which serves as

the basis for most withdrawal measuring systems currently in use at pediatric hospitals in

this country (Figure 2). The Finnegan scale measures 21 signs of withdrawal and allows

scores to be obtained at regular intervals during a twenty-four hour period. The scores

obtained serve as a means for communication regarding withdrawal severity within research

studies, as well as a clinical measure utilized when making treatment decisions.

When abstinence scores for an infant exposed to opiates reach a particular

threshold, pharmacotherapy may be used to alleviate withdrawal symptoms. Treatment is

usually initiated within the first days of life. Symptoms are brought under control and the

5
infant is gradually withdrawn from the medication. Medication for withdrawal has typically
consisted of either opiate substitutes,31

34 35

or nonspecific depressants such as

phenobarbital,36 diazepam,31 and chlorpromazine.34,36,37 Paregoric, a tincture of opium, is
generally considered the treatment of choice for NAS in this country.38 Phenobarbital is
often added or used as a second line drug for symptom control. Although morbidity
associated with NAS is decreased with treatment, therapeutic management may require a
prolonged hospital stay.

Methadone maintenance during pregnancy
It has been reported that entry into a methadone maintenance program serves to
encourage better participation in prenatal care and provide a more stable environment for
pregnant opiate addicts.39,40 Methadone is a long-acting synthetic opioid that can be taken
by mouth, thereby reducing the risk of infection acquired by the sharing of contaminated
needles or syringes as in heroin use. Methadone blocks the euphoria produced by heroin
and blunts the appetite for repeated administration of opiates. A free and regular supply of
methadone from an established clinic also decreases the likelihood that patients will engage
in prostitution or criminal activities which are detrimental to their physical and mental well¬
being. Also, it has been argued that with steady methadone maintenance the fetus would
not suffer from fluctuating levels of opiates and therefore the incidence of intrauterine
withdrawal would be less.40 It has been shown that methadone maintenance, in conjunction
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with adequate prenatal care, significantly reduces the incidence of medical and obstetrical

complications and prematurity.41 Studies have also consistently found differential effects of

heroin and methadone on birth weight, with higher birth weight infants born to women

maintained on methadone.24 42

It has been suggested that methadone produces more severe withdrawal

manifestations than heroin.34 35 However, measurement of heroin intake is rarely possible,

and most studies have been laden with the dilemma of concurrent poly-drug use. The

severity of the neonatal abstinence syndrome may largely be determined by total

intrauterine drug exposure.43 44 Many studies have debated the relationship of total

maternal methadone intake, and by extension total fetal exposure, to the severity of

subsequent neonatal withdrawal symptoms.38 45 46 Doberczak et al,46 in 1993, studied a

group of 21 methadone-dependent women and their infants to define the relationship

between neonatal opiate withdrawal and maternal methadone dose. They found that higher

initial plasma methadone levels were associated with more rapid declines of drug levels in

methadone-exposed neonates. The more rapid rate of decrease in serum methadone

levels after birth correlated significantly with acuity of central nervous system withdrawal

signs observed in their sample of infants. These results are consistent with animal studies

which have shown that methadone accumulates in the non-human primate brain during

gestation, resulting in significantly higher brain levels compared with fetal plasma levels.47 48

In addition, intrauterine exposure of the fetal brain to opiates promotes regional
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development of specific opiate receptors and suppresses neurotransmitter formation and

function.26 49 Thus, a more rapid decline in methadone levels in the first hours after delivery

would produce a rapid shift of drug out of brain tissue, leading to increased availability of

specific opiate receptors as well as rapid replenishment of neurotransmitters. In the

presence of increased receptor sites, this replenishment of neurotransmitters would

produce neuronal excitability, clinically manifested as central nervous system signs of

withdrawal such as irritability, tremors, hyperreflexia, and possibly seizures.46

With the potential for a more severe withdrawal course in infants exposed to

methadone, the suggestion has been made that lowering dosages of methadone late in

pregnancy may ameliorate neonatal opiate withdrawal, and thereby benefit the mother and

infant.46 50 However, methadone regimens are generally individualized to determine the

dose that will prevent the development of withdrawal symptoms in a pregnant woman. If

the reduction of methadone dosage is attempted, there is always the fear of fetal instability

from withdrawal,51 or the possibility of fetal death.52 In addition, dosage reduction carries

the risk of maternal discomfort and self-medication with street drugs, thus increasing

neonatal morbidity and decreasing the overall value of methadone maintenance to the
health of the woman.

8

Outcome after fetal opiate exposure
Maternal opiate addiction is associated with increased perinatal morbidity and

mortality.53 Problems associated with heroin use during pregnancy include first-trimester

spontaneous abortion, premature delivery, meconium staining, and maternal and neonatal

infections.54 In general, studies that have compared birth outcomes of opiate exposed

infants and non-drug exposed infants have consistently found opiate exposed infants to

have lower birth weights than comparison infants.4142 55 56 Although the birth weights of

methadone exposed infants are higher than those of heroin addicts, they are still less than

nonaddicted controls.57 In addition, numerous studies have now replicated the finding that

prenatal opiate exposure reduces head circumference.4142 58 Similar findings in animal

models that control for exposure to other drugs such as alcohol or tobacco, and for poor

maternal health support the finding of an effect of opiates on fetal growth.59 Prenatal

exposure to opiates may contribute significantly to an increased incidence of sudden infant

death syndrome (SIDS)7. In some studies, the incidence of SIDS is eight times that

reported for non-opiate-exposed infants.60'62

Past the neonatal period, a number of studies have documented small, and not

usually statistically significant, delays in the acquisition of developmental skills as measured

by the Bayley Scales of Infant Development.56 58 62 63 However, much more consistent

across studies have been the findings of persistent problems in poor motor coordination,

high activity level, and poor attention among opiate-exposed infants in the first year of
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life.64,65 Similarly, opiate-exposed school-age children show higher activity levels, are often

impulsive with poor self-control, show poor motor coordination, and have more difficulty with

tasks requiring focused attention.66,67 Maternal poly-drug use has been a major

confounding factor in studies investigating the effects of prenatal exposure to illicit drugs.

As well, the effect of the care-taking environment for children in substance-abusing families

is undoubtedly a significant factor in developmental outcome, and has not consistently been

controlled for in scientific studies.

Cocaine use in pregnancy
Cocaine is one of the most frequently used illicit drugs, with national trends

indicating that cocaine, and in particular crack, continues to dominate the drug scene.3

Although overall use of cocaine appears to have leveled off in most cities in the United

States, some indicators point to an increase in the number of female cocaine users.3 Crack

remains the most popular form of cocaine, presumably due to the ready availability and low

cost of the drug. In Philadelphia, a large rock, or boulder, sells for about five dollars. In

Seattle, little bits of crack called kibbles sell for one dollar.3 With crack so easily available,

the incidence of cocaine use in pregnancy has been reported at 10 to 19%.4,68-70

Cocaine is a powerful stimulant drug that in its freebased form, crack, can be

smoked to induce short periods of intense euphoric feelings, during which energy and self¬

esteem are enhanced and anxiety are decreased.71 However, within hours of use,
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cocaine's rebound effects result in anxiety, exhaustion, and depressive feelings. The

dependent person takes cocaine repeatedly to avoid the crash rebound effects. Chronic

use can result in psychologic and physical symptoms, including paranoid and mood

disorders, weight loss, and decline in judgment.72 In adults, the acute and chronic effects of

cocaine are demonstrated through significant alterations of central nervous system

function.11,73

Due to cocaine’s low molecular weight and its water and lipid solubility, it readily

crosses the placenta and the fetal blood brain barrier.74 Plasma cholinesterase, which

inactivates cocaine, is relatively deficient in the mother and fetus, possible resulting in a

greater time of exposure to the active drug. One adverse effect of cocaine on the fetus is

uterine vessel vasoconstriction with reduced uterine blood flow and oxygen transfer.75

Experiments in animals have also suggested a teratogenic effect,76 and permanent

degeneration of nerve terminals in adult animals.77,78 Thus, cocaine may have direct

neurotoxicity or indirect effects via vasoconstriction on the developing nervous system.

Cocaine and central nervous system development
The primary central nervous system (CNS) action of cocaine occurs through the

monoaminergic neurotransmitter systems including dopamine, norepinephrine, and

serotonin (5-HT). Cocaine blocks the reuptake of dopamine, norepinephrine, and 5-HT by

the presynaptic neuron, a process that is primarily responsible for inactivation of

neurotransmitters.79 Blocking reuptake leaves more monoamine neurotransmitters

available within the synaptic space and results in enhanced activity of these agents in the

CNS. The various dopamine-rich areas of the brain are involved in a number of basic

neuropsychological functions including arousal and attentional modulation, the regulation of

anxiety and other emotional states, and the reinforcing properties basic to stimulant

addiction in adults. In fetal brain development, monoaminergic neurotransmitters are critical

for the definition of brain structure and neuronal formation through their effects on cell

proliferation, neural outgrowth, and synaptogenesis.80,81 Alterations in developing

monoaminergic systems may lead to mistimed neurogenesis, and resultant alterations in

synaptic connections.82 In addition, prenatally cocaine-exposed infants might be expected

to be compromised specifically in areas such as reactivity, capacity to modulate levels of

arousal in response to stimulation, and attentional regulation.83

Perinatal complications associated with cocaine use
Numerous reports have described significant obstetric and neonatal complications

associated with maternal cocaine use during pregnancy. Among the most compelling

findings are consistent descriptions of increased rates of spontaneous abortions, abruptio

placentae, and meconium-stained amniotic fluid.17,28,68,84 Intrauterine growth retardation

has been found in all studies of reasonable size in which cocaine-exposed neonates were

compared with non-drug-exposed newborns.18,28,68,85,86
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Increased rates of prematurity and lowered gestational age in cocaine-exposed

pregnancies have been found,17 86 88 suggesting that prematurity or its complications may

be indirect mechanisms by which cocaine’s neurodevelopmental effects are expressed.

Alternatively, premature birth may be a marker for mothers with greater dependency on

drugs, a heavier use of drugs, or significant socioeconomic disadvantages.72 Marijuana

use, alcohol use, and cigarette use have also been shown to be significant independent or

interactive contributors to reduced fetal health in samples of poor, urban, minority pregnant

women.18,84 Some available studies have had methodologic problems that prevent clear

attribution of the poor medical outcomes of cocaine-exposed pregnancies to cocaine use

alone. These problems include poorly defined or highly selective samples, misidentification

of subjects, lack of appropriate comparison groups, and retrospective sampling.89

Infant outcome after prenatal cocaine exposure
Exposure to cocaine and other drugs places infants at risk for developmental

dysfunctions. For example, infant neurological examinations soon after birth have

documented increased tremors, irritability, and hypertonicity in infants exposed to cocaine.31

90 91 The Brazelton Neonatal Behavioral Assessment Scale (NBAS) has been the most

consistently used assessment of newborn neurobehavioral characteristics,92 '94 and it is

frequently the outcome measure of choice in studies of the neurobehavioral effects of

prenatal drug or potential teratogen exposure.17,65 95 In three studies to date, reporting on
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cocaine exposure without concomitant opiate use, and with or without concomitant alcohol

use, findings have been inconsistent.1 84,95 Chasnoff and colleagues1 found impairments of

orientation, motor, and state regulatory behaviors on the NBAS. In contrast, Coles et al84

reported that NBAS scores for all newborns fell within a clinically normal range regardless of

cocaine or alcohol exposure. Although significant differences emerged between groups for

autonomic regulation and for abnormal reflexes, the less optimal performance was not

consistently more frequent among the cocaine-exposed group only, and no clear patterns of

effect emerged. Finally, Eisen and colleagues,95 studying neonates who were urine screen

positive only for cocaine at birth and whose mothers denied opiate use, found significant

differences in habituation performance as assessed by the NBAS. Habituation is involved

with attention and information processing and perhaps learning in infants.96 Depressed

habituation performance on the NBAS in infants exposed to cocaine would suggest a link

between the effects of cocaine on the developing brain and neurobehavioral outcome.

In early reports regarding the long-term developmental outcome of infants exposed

to cocaine as well as combinations of heroin, methadone, and marijuana, cocaine exposure

was predictively linked to moderate to severe developmental delays across diverse

developmental domains.97 However, subsequent studies have reported mild to no

impairments in overall developmental functioning in cocaine-exposed children compared to

non-exposed groups.98 99 The findings from a 3-year outcome study by Azuma and

Chasnoff100 indicated that prenatal substance exposure had a significant effect on cognitive
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abilities as measured by the Stanford-Binet scale. It was acknowledged, however, that the

nature of the effect on intellectual outcome is complex, due to the influences of home

environment, child behavior, and head circumference which confound studies with this

group of children. Therefore, other causal models for attributing poor Stanford-Binet scores

to a drug exposed population of children could not be ruled out. Therefore, such factors as

socioeconomic status, behavioral characteristics, and quality of the home environment

continue to complicate the ability to draw conclusions from studies of drug exposure in

children.

Interactive effect of cocaine and opiates
Infants with combined exposure to narcotics and cocaine have been shown to have

a worse perinatal outcome when compared to other drug exposures in pregnancy.88 Among

women maintained on methadone for opiate addiction, concomitant, regular cocaine or

crack use has been reported in 20 to 60%.8,9 Combinations of opiate and cocaine use

during pregnancy raise concerns about a potentially interactive effect on the withdrawal

syndrome, and exacerbation of adverse perinatal outcomes. In a phenomenon called the

“kindling effect," repeated doses of cocaine result in progressively increasing central

nervous system sensitivity, thereby increasing reactivity to the central effects of other

drugs.101 102 Pinel and Van Ott reported that repeated cocaine administration in animals

leads to more severe withdrawal from a second drug such as heroin and amphetamines.103
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There are conflicting reports published regarding the interactive effect between

cocaine and opiates. In adult opiate addicts applying for methadone maintenance, it has

been reported that cocaine significantly lowered levels of naloxone-precipitated

withdrawal.104 However, adult patients in another study reported that cocaine use

precipitated symptoms similar to opiate withdrawal.105 For human infants potentially

interactive effects between cocaine and opiates on neonatal withdrawal have been reported

for infants exposed to heroin and cocaine prenatally. Fulroth and colleagues studied the

withdrawal course of 86 infants after maternal heroin use.106 Seventeen infants were

exposed to both heroin and cocaine, and 14 to heroin alone. Using the Finnegan scoring

system, infants were treated for withdrawal when scores were greater than 12 over an eight

hour period in the first five days of life. In their population of patients a significant difference

was found between the withdrawal course of heroin-only infants and those exposed to both

opiates and cocaine. They found that 21% of the infants exposed only to heroin required

treatment for withdrawal, compared with 47% of the infants exposed to both heroin and

cocaine. The conclusion drawn from this data was that cocaine had a synergistic effect on

the withdrawal syndrome seen after

in utero heroin exposure.

In contrast, in the retrospective study by Mayes and Carroll,107 suggested that the

effect of cocaine, if any, on neonatal opiate withdrawal was most notable in the initial phase

of withdrawal. In their study, 68 women and infant pairs were analyzed for measures of

withdrawal severity. In that cohort, cocaine exposure resulted in significantly higher first
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withdrawal scores, but there were no significant differences in the amount of time on

withdrawal medication or the maximum doses of paregoric required for withdrawal

treatment.
Another study to look at the specific question of cocaine effects on opiate

withdrawal was performed by Ryan et al.108 In that study, 50 methadone-exposed infants

were compared with 50 methadone and cocaine-exposed infants, using parameters of

neonatal morbidity and mortality, as well as abstinence scoring immediately after birth to

determine outcome. The most significant findings included lower birth weight, length, and

head circumferences for cocaine-exposed infants when compared with a group of infants

not exposed to cocaine or methadone. In addition, their data suggested a higher rate of

fetal loss and infant mortality after cocaine exposure in pregnancy. To determine the effect

of cocaine exposure on neonatal abstinence severity in that population, Ryan et al

compared individual symptom frequency, as scored on the Finnegan scale. It was noted

that episodes of abstinence symptoms occurred less frequently in infants exposed to a

combination of cocaine and methadone in 19 of the 21 symptom categories. This trend was

not found to be statistically significant, thus the authors concluded that cocaine exposure

had no effect on the severity of withdrawal in opiate-exposed infants.

Finally, Doberczak and colleagues examined the effects of gestational age on the

neonatal abstinence syndrome, with and without concomitant cocaine exposure.109 In this

cohort of methadone-maintained mothers, severity of abstinence symptoms correlated with
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maternal methadone dosage, but was not influenced by maternal multiple drug use.

Therefore, with the results of current research available, the question of how cocaine affects

the severity of neonatal withdrawal from opiates remains inadequately answered. It could

be hypothesized, based on a review of the literature, that cocaine exposure would

exacerbate the central nervous system irritability that is a central aspect of the neonatal

abstinence syndrome. Theoretically, the direct stimulant effects of cocaine would mimic

opiate withdrawal symptomatology early on in the neonatal course, causing earlier and

more frequent need for treatment of withdrawal in dually exposed infants. In addition, the

direct effects of cocaine on neurodevelopment of the fetus could potentially cause an

anatomic or neurophysiologic basis for a longer-term altered neurologic status in cocaine-

exposed infants. This altered baseline of functioning could affect the appearance of

neonatal withdrawal symptoms, such that the neonatal abstinence syndrome is essentially

changed in these infants. Delineating such questions may serve to improve the treatment

and understanding of long-term outcome in infants exposed to narcotics and cocaine

concomitantly

in utero.
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PURPOSE
The purpose of the present study was to prospectively examine the following
hypothesis: Cocaine use among pregnant women maintained on methadone increases the
duration and the severity of the withdrawal syndrome among their infants. The severity of
withdrawal was indexed by infant length of stay in the hospital, duration of treatment with
medication, first withdrawal scores, and the dosages of withdrawal medications used.
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METHODS
Study sample
The study sample consisted of pregnant narcotic-addicted women maintained on

methadone, and their infants, born at Yale New Haven Hospital (YNHH). Women were

recruited to participate in the study through a methadone maintenance program for opiate

addicted individuals offered through the Substance Abuse Treatment Unit of the Yale

University School of Medicine Department of Psychiatry. Women eligible for the study were

participants of the methadone program who had delivered a child while on methadone,

during a period of 23 months (October, 1995 - August, 1997). During this period, 24 infants

were born at YNHH to methadone-maintained women.

All of the pregnant women in the study sample received their daily methadone dose

at the Substance Abuse Treatment Unit. Urine screens for elicit drugs (cocaine, heroin,

methamphetamine, benzodiazepines, and barbiturates) were performed routinely and

randomly during the mothers’ methadone maintenance course. Women participated in

regular group counseling sessions for pregnant substance users as a part of the methadone

maintenance program, with direct regular contact with a trained substance abuse treatment

nurse.

Recruitment to the study was performed through the group counseling sessions,

with study coordinators obtaining consent from the mothers during their pregnancy to have

access to the drug treatment records of the mothers, as well as follow the infant in the
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hospital for narcotic withdrawal. Informed consent for participation in the study was

obtained by one of the researchers (B.T.). All pregnancy, drug history, and infant

information was gathered with the maintenance of strict confidentiality, as approved by the

institutional review committee of the Yale University School of Medicine.

Study protocol
During pregnancy, information was gathered on daily methadone dose, urine

toxicology, pregnancy complications, and medication use. All infants were delivered at Yale

New Haven Hospital, and mother and infants charts were reviewed for prenatal and delivery

information at the time of hospitalization. Infants were routinely admitted to the Special

Care Nursery and observed for withdrawal symptoms within the first 48 hours of life. Each

infant was transferred to the Children’s Clinical Research Center within 24 hours of

beginning medication for narcotic withdrawal when it was determined that there were no

other complications needing intensive care unit observation. Gestational age was

estimated by attending pediatricians in the newborn nursery using the Ballard criteria.110

Abstinence scoring
Drug withdrawal assessment was performed by nursing staff in the CCRC trained to

use the abstinence scoring system of Finnegan,33 modified (see Figure 2), which measures

21 signs of withdrawal including increased tone, tremulousness, tachypnea, decreased
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sleep, and feeding disturbances.

Scores were assigned every eight hours, and the initial

assessment was made in the first eight hours after birth. Nursing staff performing the

assessments were blinded to the drug history of the mother, with information only that the

mother had taken methadone during pregnancy. Treatment was routinely begun for

withdrawal when withdrawal scores exceeded 12 for two consecutive scoring periods. The

first drug prescribed for withdrawal symptoms was paregoric in all infants. If the infant

remained symptomatic, phenobarbital was added. In one infant, no medications were used

to treat narcotic withdrawal specifically. An increase or decrease in dosage of withdrawal

medication was determined by the infant’s withdrawal symptoms. Infants were always

weaned off medication before discharge from the hospital and were not transferred to

another institution or released home until they were symptom free.

Information regarding the infant’s withdrawal course was recorded on a daily basis,

focusing on the following parameters: individual shift withdrawal scores; total daily

withdrawal score; medication type, dose, and frequency of administration; weight gain;

feeding type and amount; and frequency of perinatal problems such as jaundice, respiratory

distress, or dysmorphic features.

Statistical analysis
We compared groups with a one-way ANOVA test, and Pearson’s chi-square. P<

.05 was considered significant. All data are represented as mean (Standard Deviation).
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RESULTS
Twenty-four women who were receiving methadone during pregnancy through

SATU, and who delivered infants at YNHH were identified in this study period. One mother

refused access to her drug history information as a part of the study, and thus data on the

infant were not included in the present analysis. In the final analysis, data from 23 mother

and infant sets were used.

Table 1 shows the demographic characteristics of the sample. Women in this

sample were usually in their mid-twenties (mean 26.9, S.D. 5.4), and had had multiple

previous pregnancies (mean 3.7, S.D. 2.0). The sample was predominantly Caucasian

(56.5%) with 26.1% of Hispanic ethnicity and 17.4% African-American. The HIV status was

known for 17 women, one of whom was positive. Of the women for whom hepatitis B and C

test results were available (n = 20), three were positive (13%), with one positive for hepatitis

B and C, and two for hepatitis C only. Fifteen of the 23 mothers presented to the

methadone clinic at some point in their pregnancy, and the remaining eight were already in

the methadone program when they became pregnant. Mothers had been receiving

methadone for a mean of 26.7 weeks (SD 12.3) at the time of delivery.

Maternal urine toxicology
Fourteen mothers (60.9%) who were receiving methadone also reported regular use

of cocaine or had positive urine screens for cocaine during pregnancy. When mothers who
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used cocaine during their pregnancy in addition to methadone were compared to mothers

maintained on methadone who did not use cocaine, there were no differences in maternal

age, ethnicity, number of pregnancies, or the frequency of tobacco use. There was no

difference in methadone dose at the time of delivery between the two groups. There

seemed to be a trend toward later enrollment in the methadone program for mothers who

also used cocaine during pregnancy, however, the difference did not reach statistical

significance. The mean gestational age at enrollment for non-cocaine exposed of 8.2

weeks (SD 8.4) and for cocaine-exposed of 12.0 weeks (SD 11.69), F=.7006, p=.4120.

Other drug use in pregnancy was similar between the two groups, with no positive urine

screens for amphetamines, and near equal numbers in each group using benzodiazepines.

Of those who used cocaine during pregnancy, three (21.4%) also had positive urine screens

for benzodiazepines. Of the nine mothers who did not use cocaine while maintained on

methadone, two (22.2%) had positive urine screens for benzodiazepines throughout

pregnancy.

Perinatal outcome
There were seven male and sixteen female infants. As indicated in table 2, the

mean gestational age for the overall sample was 37.5 weeks by Ballard criteria (S.D. 3.7)

with a range of 27 to 41 weeks. The mean birth weight for the overall group was 2646 g

(S.D. 692) and four infants were small for gestational age. The most frequent perinatal
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complication was low birth weight, with 39.1% of the overall sample born at under 2500

grams. In addition, 34.8% of the group of 23 infants were delivered at a gestational age of

less than 37 weeks. One infant was bom at 27 weeks, with a birthweight of 830 grams.

There was a trend toward the cocaine-using women to have more frequent preterm labor,

and a greater number of perinatal problems, however the differences were not found to be

statistically significant. Fourteen infants (60.9%) had additional complications during

hospitalization. Of these, the most common was hyperbilirubinemia (21.7%), with two

infants with positive Coombs results. Three infants (13%) had a hospital course that was

complicated by infection. Similarly, three infants (13%) were observed to have at least one

episode of apnea while in the hospital. Two infants were diagnosed with a cardiac

arrhythmia, and one infant was found to have a heart murmur, macrocephaly, and

dysmorphic features. One infant tested HIV positive during the first month of life.

The infants withdrawing from methadone spent an average of 34.3 days (S.D. 18.7;

range 13-85) in the hospital. Infants were treated with medication for withdrawal for an

average of 27.6 days (S.D. 19.7; range 0-81). The majority of infants showed withdrawal

symptoms within the first 24 hours (mean 13.2 hours, S.D. 10.8), and were started on

medication for withdrawal at an average of 43.3 hours of age (S.D. 56.2; range 4-264).

Paregoric was the first medication used in all infants, and phenobarbital was added to

paregoric for treatment of continued withdrawal symptoms in three cases. One infant

required no medication for withdrawal.

25

Withdrawal course by cocaine exposure status
Several parameters were used to compare the withdrawal course of infants whose

mothers used cocaine in addition to methadone (n=14) and those who did not (n=9). The

severity of the withdrawal course was measured by the first and maximum withdrawal

symptom scores, the maximum dose of paregoric required, the length of stay in the

hospital, the total number of days on withdrawal medication, and the addition of

phenobarbital to paregoric for adequate withdrawal treatment. Complications which

affected the hospital course of the infant, such as prematurity or apnea, were noted and

compared between the two groups as a measure of poor perinatal outcome.

When infants exposed to cocaine plus methadone were compared to those whose

mothers did not use cocaine, the cocaine exposed group trended toward a shorter

withdrawal course, with trends toward a shorter duration of medication treatment, shorter

length of stay, and fewer number of days on the highest doses of paregoric. However, the

statistical differences were not significant to show a strong association between cocaine

exposure and a shorter withdrawal course. Cocaine-exposed infants required medication

for withdrawal symptoms at a later age than the methadone-only infants (53.0 versus 28.2

hours of life), but the difference did not reach statistical significance. Also, cocaine-exposed

infants tended to require a fewer number of days at the highest doses of paregoric (3.9

versus 7.9 days), a difference that was not statistically significant. There were no

differences in first withdrawal scores, age at first withdrawal symptoms, highest dose of
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paregoric required, duration of medication treatment, or length of stay in the hospital

between the cocaine exposed and cocaine non-exposed groups.

Three infants required the addition of phenobarbital to paregoric for the treatment of

more severe withdrawal symptoms. Two infants who received phenobarbital were exposed

to cocaine, and one was exposed only to methadone. One infant who was not exposed to

cocaine prenatally required no treatment with paregoric for withdrawal, and one who was

exposed to cocaine in addition to methadone required only two days of medication

treatment for withdrawal. The number of infants experiencing complications while in the

hospital was six (66.7%) for the cocaine-exposed and eight (57.1%) for the group not

exposed to cocaine, a difference that did not reach statistical significance. Those who were

born at less than 2500 grams were approximately evenly distributed between groups, with

four (44.4%) in the group not exposed to cocaine and five (35.7%) in the cocaine-exposed

group of infants. In addition, one infant was born at under 30 weeks, and was a part of the

cocaine-exposed cohort. However, there was no difference overall in gestational age

between the two groups (37.9 weeks and 37.3 weeks). Of the four infants who were

classified as small for gestational age, three were in the cocaine negative group and one

was cocaine-exposed.

27

Effect of maternal methadone dose
In the present analysis, cocaine exposure was not significantly correlated with

specific measures for severity of narcotic withdrawal, and only showed trends toward a less

prolonged course of treatment. However, maternal methadone dose at the time of delivery

did seem to be a significant contributor to the quality of the infant’s withdrawal course.

Maternal methadone dose was positively correlated with the number of days that infants

spent at the highest doses of paregoric [correlation coefficient (r) = .53, p < .01], In

addition, there was a fair correlation between methadone dose at the time of delivery and

length of stay of the infant in the hospital (r=.37, p < .08), and the highest dose of paregoric

required for treatment of withdrawal (r=.23, p <.30). There was a negative correlation at a

fair level between maternal methadone dose and the age of the infant at the time of first

withdrawal symptoms (r= -.37, p <.09), and with age at the time of first medication treatment

(r= -.24, p <.30). The infants (n=3) who required the addition of phenobarbital to paregoric

for adequate treatment of withdrawal had been exposed to methadone at an average daily

dose of 90 mg at the time of delivery, whereas the overall group mean daily dose was 77.8

mg.

Effect of benzodiazepine exposure
During the data collection phase of the study, it became evident that a number of

infants were consistently exposed to benzodiazepines in utero. This drug exposure
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information was incorporated into a separate analysis to study the effect of benzodiazepine

exposure on infant withdrawal course. We compared infants who were exposed to

benzodiazepines in addition to methadone to the infants who were exposed to methadone

without benzodiazepines. The cocaine exposure status was not used as a factor in this

portion of the analysis. When mothers who used benzodiazepines were compared to

mothers who did not use benzodiazepines during pregnancy (Table 4), it was found that

benzodiazepine users were maintained on a higher dose of methadone and had a

significantly higher daily dose of methadone at the time of delivery (F=9.92, p = .005). The

infants of benzodiazepine-using mothers had significantly longer hospital stays (F=8.29, p

<.01), longer duration of withdrawal medication treatment (F=10.37, p < .01), and spent

more days at the highest doses of paregoric (F=5.36, p < .05). There were no significant

differences in first withdrawal score, age at first withdrawal score, age at first medication

treatment, or the highest dose of paregoric required to treat withdrawal symptoms. The

number of complications experienced while in the hospital was equal for infants exposed to

benzodiazepines and those who were not exposed to benzodiazepines (.94 and 1.20

respectively). The addition of phenobarbital was required for the treatment of withdrawal in

one infant (5.6%) not exposed to benzodiazepines, and two infants (40%) with

benzodiazepine exposure.
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DISCUSSION
Relationship of cocaine exposure to severity of withdrawal
In the present study, the relationship between cocaine exposure and the severity of

the neonatal abstinence syndrome was investigated in a prospective manner. The primary

hypothesis of this study was that a combination of methadone and cocaine use during

pregnancy contributed to a more prolonged and potentially more severe neonatal

withdrawal course than would be expected with exposure to methadone alone. This

hypothesis was not proven by the findings in this prospective cohort. On the contrary, there

is a suggestion that in the group exposed to cocaine in addition to methadone there was a

trend toward a shorter and less severe withdrawal course. Although not found to be

statistically significant, the data suggested that infants who were exposed to cocaine had a

shorter duration of treatment with withdrawal medications, shorter length of stay, and fewer

number of days on the highest doses of paregoric. These findings suggest that the effect of

cocaine on withdrawal from methadone in infants is small, and either has no contributory

effect to the overall severity of narcotic withdrawal, or accounts for only a mild degree of

shortening in the duration of withdrawal symptoms.

The results of this study are in contrast, somewhat, to the retrospective view

performed by Mayes and Carroll,107 looking at a cohort of women who received methadone

during pregnancy through the same treatment program as women in the present study.

Data from 68 women and infant pairs were collected, and analyzed for measures of
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withdrawal severity which parallel the present study. In that cohort, cocaine exposure
resulted in significantly higher first withdrawal scores, but there were no significant
differences in the amount of time on withdrawal medication or the maximum required doses
of paregoric. Those results suggested that the effect of cocaine, if any, on neonatal opiate
withdrawal was most notable in the initial phase of withdrawal.
Another study with results conflicting with the present findings was performed by
Fulroth et al.106 They studied the withdrawal course of 86 infants, 17 of whom had positive
urine screens for both heroin and cocaine, and 14 for heroin only at the time of birth. They
found that 21% of the infants exposed only to heroin required withdrawal treatment,
compared with 47% of infants exposed to both heroin and cocaine. The conclusion drawn
from this data was that cocaine had a synergistic effect on the withdrawal syndrome seen
after in utero heroin exposure.
However, a third study, performed by Ryan et al,108 found that cocaine exposure
may have lessened or had no effect on the severity of withdrawal in opiate-exposed infants.
The most significant findings included lower birth weight, length, and head circumferences
for cocaine-exposed infants when compared with a group of infants not exposed to cocaine
or methadone. In addition, their data suggested a higher rate of fetal loss and infant
mortality after cocaine exposure in pregnancy. It was noted that episodes of abstinence
symptoms occurred less frequently in infants exposed to a combination of cocaine and
methadone in 19 of the 21 symptom categories on the Finnegan scale. This trend was not
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found to be statistically significant, and thus the conclusion of the authors was that maternal

cocaine use had no effect on the severity of neonatal abstinence syptomatology. However,

it might be suggested, that had a larger population of infants been studied, there may have

been significance to the trend toward a less severe withdrawal course in the cocaine-

exposed infants.

That we did not find a significant effect of cocaine on neonatal narcotic withdrawal is

most consistent with the results of Ryan et al,108 Mayes and Carroll,107 and studies of opiate

withdrawal in adults who are also using cocaine.104 However, Fulroth and colleagues106

found an increased severity of withdrawal in infants exposed to cocaine in addition to

heroin. Three aspects of the present study may account for these differences. The present

study prospectively followed women through pregnancy to identify specific drug exposure in

the newborn, as opposed to relying solely on the results of urine toxicology at the time of

delivery. Second, all infants were followed prospectively for withdrawal symptoms in a

study protocol that was pre-defined and monitored specifically for the reduction of bias in

scoring. Third, all of the women identified as study subjects were enrolled in a methadone

maintenance program, with monitoring for concomitant health problems and illicit drug use.

Methadone dose effect on withdrawal severity
Consistent with previous research,30 45 111 in our study there was a significant

positive correlation between maternal methadone dose at the time of delivery and the
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severity of withdrawal as measured by the number of days that infants spent on the highest

doses of paregoric, and the length of stay of the infant in the hospital. Studies of the

predictive factors for the severity of neonatal withdrawal from methadone have most often

found maternal methadone dose to be the most significant predictor of withdrawal

severity.30'45,111 Doberczak et al46 found that higher initial plasma methadone levels were

associated with more rapid declines of drug levels in methadone-exposed neonates. The

more rapid rate of decrease in serum methadone levels after birth correlated significantly

with acuity of central nervous system withdrawal signs observed in their sample of infants.

In an earlier study by Ostrea et al,30 neonatal narcotic withdrawal was examined

prospectively to determine the effect of multiple factors on severity of symptoms. In a large

cohort of infants, they found that the only significant correlation with severity of withdrawal

was with the maternal methadone dose. Similarly, in a chart review of 40 women treated

with methadone during pregnancy, Malpas et al112 found a strong association of higher

maternal methadone doses with increased length of stay and duration of medication

treatment for infants experiencing opiate withdrawal symptoms.

With such clear evidence that maternal methadone dose positively correlates with

an increased severity of neonatal withdrawal, it has been suggested that women should be

placed on lower-dose methadone regimens in the later stages of pregnancy,30,45,11V112 or

that opiate addicts should be detoxified during pregnancy.50 In contrast, in our study

population, the methadone treatment program tended to increase the daily dose of
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methadone when there was evidence that a woman was also using cocaine in pregnancy.

Thus, cocaine use could have been indirectly associated with a more severe narcotic

withdrawal course. However, it is important to note, there was no difference in the mean

methadone dose at the time of delivery between cocaine and non-cocaine users in our

study.

In the present study, there was a difference in the total number of weeks that

women received methadone during pregnancy. Although not found to be statistically

significant, there was a trend toward later enrollment in the methadone program by about

four weeks for the mothers who also used cocaine during pregnancy. Thus, women who

used cocaine were more likely to have also used illicit opiates for a longer duration during

their pregnancy, and may have had lower cumulative exposure to methadone over the

gestation. Many have suggested that the relationship between methadone dose and

severity of withdrawal is actually due to an accumulation of methadone in fetal tissues

which occurs particularly in the last trimester of pregnancy.27 109 Also, there is evidence that

heroin use during pregnancy produces less severe neonatal withdrawal manifestations than

methadone maintenance.113'116 Therefore, the tendency for infants to be exposed to less

cumulative methadone and more heroin

in utero may account for the trend toward a less

severe withdrawal course in our cohort of cocaine-exposed infants.
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Benzodiazepine exposure effect
A significant finding from our data was that benzodiazepine (BZD) exposure was

associated with longer hospital stays, longer duration of withdrawal medication treatment,

and more days at higher doses of paregoric for the infants. The finding of a more severe

withdrawal course in these infants was in agreement with published literature on newborn

outcome after prenatal BZD exposure. BZDs easily cross the placenta and accumulate in

the fetal adipose tissue.117,118 There is evidence that neonates have a limited capacity to

metabolize BZDs and may experience symptoms of intoxication or passive addiction after

prenatal exposure.119 BZD intoxication symptoms have been described as low Apgar

scores, hypotonia, hypothermia, respiratory and neurologic depression.120 Withdrawal

symptoms in newborns exposed to diazepam

in utero have been described as a high

pitched cry, increased muscle tone, and increased regurgitation.121 Laegreid et al122 studied

17 infants of women who had been prescribed benzodiazepines during pregnancy, looking

at neurologic and behavioral conditions in the neonatal period. Their results were

significant for diminished reflexes such as the Moro and optical blink reflexes in infants

exposed to BZD, when compared to a reference group of infants without a history of drug

exposure. In addition, there were increased findings of drowsiness, tremor, startling, and

poor sucking in the BZD-exposed group.

The similarity in clinical appearance of benzodiazepine-exposed and narcotic-

exposed infants reveals the difficulty of sorting out the impact of poly-drug exposure on

neonatal outcome. First, testing for benzodiazepines was not routine in the first year of

enrollment in our study, and maternal reporting of illicit drug use is not consistently reliable.5

Thus, infants who were exposed to benzodiazepines may have been missed, and a

misclassification of subjects may have occurred. Second, women who were found to be

abusing benzodiazepines while on methadone maintenance routinely had the daily doses of

methadone increased. In this manner, the effect of benzodiazepines on the severity of

narcotic withdrawal symptoms was intensified. Third, the abuse of benzodiazepines may

often be associated with an increased severity of illicit opiate abuse or with other drug use

in pregnancy. Therefore, the question of the specific effects attributable directly to

benzodiazepines is difficult to isolate. In our study, benzodiazepine exposure seemed to

correlate with a more severe withdrawal course. However, because there was an even

distribution of BZD exposure between the cocaine-exposed and non-cocaine-exposed

groups (21.4% and 22.2% respectively) there presumably was equal effect of BZD

exposure on the withdrawal symptom scoring in each group in our study.

Pregnancy complications
Although the overall group of poly-drug exposed pregnancies in our study does

appear to be at higher risk for complications than non-drug exposed pregnancies, cocaine

exposure as a single factor was not associated with an increased risk of poor perinatal

outcome in our sample. Our findings are in contrast to the results of others who have
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studied cocaine use in pregnancy.108,123'125 Most often, cocaine use in pregnancy has been

reported to be associated with prematurity, low birth weight, and decreased head

circumference.124,125 Chasnoff et al123 studied 52 cocaine-using women and compared them

to 73 women who were maintained on methadone during pregnancy. The women in the

two separate groups were similar in type of prenatal care, socioeconomic status, and

cigarette, marijuana, and alcohol use. The cocaine-using women in the study had

significantly higher rates of premature labor, abruptio placentae, fetal monitor abnormality,

and fetal meconium staining than women in the methadone group. However, there was no

effect of cocaine use on neonatal gestational age, birth weight, length, and head

circumference compared to methadone use.

The Chasnoff et al123 study group was most similar to our own, in that pregnancies

complicated by cocaine use were directly compared to those with in which the mothers used

methadone. Our cocaine-exposed sample similarly revealed a trend toward a higher rate of

preterm labor, and increased fetal distress. Notable due to the reported lessened severity

of withdrawal in preterm infants,109 there was no increased risk of prematurity in the

cocaine-exposed group in this study. In addition, we did not find a significant difference

between groups in gestational age, birth weight, or head circumference. This apparently

low incidence of perinatal morbidity attributable to cocaine exposure is consistent with the

results of a meta-analysis evaluation published by Lutiger et al.126 In their review of 20

papers dealing with the effects of cocaine use during pregnancy on pregnancy outcome, the
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analysis revealed very few adverse effects to be significantly associated with cocaine use

when compared to control groups of polydrug users. Thus, our results contribute to the

suggestion that a variety of adverse reproductive effects commonly quoted to be associated

with maternal use of cocaine may be caused by confounding factors clustering in cocaine

users.

Study limitations
Failure to find a significant effect of cocaine on neonatal withdrawal may reflect

several limitations of the present sample. First, the assignment of infants to cocaine and

non-cocaine exposed groups was based on obtaining positive urine screens for cocaine

during pregnancy in women enrolled in the methadone maintenance program. Although

urine screens were performed routinely and randomly, mothers presenting for methadone

treatment later in their pregnancy would be less likely to have had repeated urine screens.

Therefore, subjects may have been misclassified as non-cocaine using.

Another problem with the present study was the small number of subjects, and thus

the inability to show significant differences between groups due to high standard deviations.

Recruitment into the study could have been broadened to include mothers treated at

methadone maintenance clinics or delivering at hospitals separate from the YNHH system.

However, logistical matters precluded the ease with which drug use information may be

shared between institutions. The enrollment of subjects is actively being continued, such
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that the sample size of mother and infant pairs may increase, and data may be reanalyzed

at another endpoint in the near future.

Thirdly, information on alcohol use during pregnancy was limited for our sample of

mothers. Maternal reporting of substance abuse in pregnancy is consistently unreliable and

may underidentify users.5 In addition, there was no objective measure, such as blood

alcohol levels, used to detect alcohol consumption in methadone-maintained pregnant

women. This becomes important in interpreting results for any study of poly-drug exposed

infants. In particular, alcohol exposure during pregnancy has been reported to effect

newborn autonomic regulation as evidenced by increased tremors and startles,127 and by

decreased habituation response to novel stimuli such as light or sound.128 In more recent

studies, specific effects on newborn behavior attributable to alcohol exposure have not been

detected.84129 However the interactions of cocaine, alcohol, and opiates in newborns are

not well understood. This makes it difficult to conclude the amount of effect attributable to

cocaine exclusively in our study when there is little information on concomitant alcohol

exposure.

A final methodologic issue was the potential for bias to be introduced, particularly in

withdrawal scoring and the length of treatment of infants in the hospital. We used the

abstinence scoring system devised by Finnegan33 to quantitate the presence and degree of

withdrawal. All scorers were trained in using the scale and were known to be able to score

infants accurately. However, the items scored on the Finnegan scale allow for some
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subjective input by the scorer, such as the degree of tremors being judged as mild to

severe. Such subjectivity in scoring may easily be influenced by observer bias. For

instance, the nursing staff at YNHH may have had an idea of whether or not each infant

was exposed to other drugs

in utero in addition to methadone. This information is often

gained through other channels than the infant’s chart or actual urine assay results, and so

may or may not be accurate. To investigate this potential bias, we gathered information on

whether scorers believed certain infants were exposed to cocaine prenatally, then

compared that opinion with actual urine results from the pregnancies. A brief questionnaire

was given to each nurse who had cared for a given infant during hospitalization, asking

whether they knew of cocaine exposure in the infant. Data from the nursing staff who cared

for 11 of the study infants were gathered and analyzed for accuracy of the predictions. In

the overall sample, respondents were unsure of the exposure history 32.9% of the time.

However, when nursing staff expressed an opinion that an infant was exposed to cocaine,

they were correct 78.0% of the time. Therefore, although blinded to the results of maternal

urine analyses, withdrawal scorers often had an idea of whether the infants had been

exposed to cocaine

in utero, and surely held beliefs about how such exposure affected

neonatal behavior. Similarly, perceived knowledge of maternal drug use often influences

when an infant will be discharged from the hospital, and potentially the length of treatment

for withdrawal. Thus, length of stay and duration of treatment as endpoints to a study may

be inherently laden with bias.
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In conclusion, exposure to cocaine in addition to opiates during pregnancy may not

have an effect on the severity of the neonatal abstinence syndrome, as measured by length

of treatment, dosage of withdrawal medications, length of stay, and first withdrawal scores.

Further investigations that attempt to time more accurately the infant’s last exposure to

cocaine, as well as to define more clearly the level of alcohol and benzodiazepine exposure

will be useful in more precisely defining whether or not cocaine exposure further

complicates the withdrawal of the opiate exposed infant. A commonly expressed view

among women in methadone maintenance programs is that cocaine use will minimize their

infants’ withdrawal from methadone. That belief is not supported by the present study, and

based on the literature on cocaine exposure in pregnancy many mothers may be placing

their infants at increased risk of perinatal morbidity or mortality by adhering to this belief.

Thus, there is a strong clinical need for further education and monitoring in the methadone-

maintained population of women to detect and decrease polydrug use in pregnancy.
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Figure 1
Signs and Symptoms Associated with Neonatal Abstinence

Central Nervous System:

Gastrointestinal:

Irritability

Poor Feeding

High-pitched cry

Regurgitation

Exaggerated Moro Reflex

Loose Stools

Tremors

Excessive Sucking

Increased Muscle Tone

Uncoordinated Sucking

Increased Deep Tendon Reflexes
Increased Rooting Reflex

Respiratory:

Seizures

Respiratory Distress
Frequent Yawning

Metabolic:

Nasal Stuffiness

Fever

Sneezing

Sweating
Mottling
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Figure 2
Modified Finnegan Abstinence Scoring Form

On*
DATi

on*
O'ME

D

E

CENTRAL NERVOUS SYSTEM DISTURBANCES:
Irritability:
which Interferes with ability to sleep at least
2 hours after feeding
which interferes with ability to bottle feed
(requiring gavage)
inconsolable while being held
Mild tremors undisturbed
Moderate-severe tremors undisturbed
Mild tremors disturbed
Moderate-severe tremors disturbed
Increased muscle tone
Excoriation (where_)
URBANCzes:
METABOLIC/VASOMOTOR/RESPIRATORY DISTURBANCES:
Sweating
Fever < 101 (37.2-38.2)
Fever > 101 (>38.4)
Frequent yawning
Mottling
Nasal stuffiness
Sneezing
Nasal flaring
Respiratory Rate:
> 60/min
> 60/min with retractions
GASTROINTESTINAL DISTURBANCES:
Excessive sucking
Poor feeding
Regurgitation
Projectile vomiting
Loose stools
Watery stools
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N
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Table 1
Demographic Characteristics of Study Sample
n = 23

Mean

S.D.

Ranae

Maternal Age

26.9

5.4

17-38

Number of Pregnancies

3.7

2.0

1-8

Methadone Dose (mg/day)

77.8

22.5

35-120

Weeks on Methadone at Delivery

26.7

12.4

2.5-41

Maternal Ethnicitv
African-American
Caucasian
Hispanic

N 1%)
4(17.4)
13(56.5)
6(26.1)

Maternal HIV Status
Positive
Negative
Unknown

1 (4.3)
16(69.6)
6(26.1)

Maternal Hepatitis Status
Positive (B or C)
Negative
Unknown

3(13)
17(73.9)
3(13)
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Table 2
Infant Study Subjects: Perinatal Data

Cocaine Negative
N=9

Cocaine Positive
N=14

Mean (S.D.1

Mean (S.D.’l

Gestational Age (wk)

37.9(3.1)

37.3 (4.2)

F (1,21) = .03

Birthweight (gm)

2677 (620)

2627 (757)

F (1,21) = .12

Head Circumference (cm)

32.2 (2.6)

31.9(2.7)

F (1,20) = .05

Weight at Discharge (gm)

3396(1029)

3409 (897)

F (1,21) = .001

Complications:

N (%)

N (%)

Delivery @ <37 weeks
Fetal distress @ delivery
Meconium stained fluid
Less than 2500 gms
Small for Gestational Age
Hyperbilirubinemia
Infections
HIV positive
Apnea
Other

3 (33.3)
0
1 (11.1)
4 (44.4)
3 (33.3)
3 (33.3)
0
1 (11.1)
1 (11.1)
6(26.1)

5 (35.7)
2(14.3)
0
5 (35.7)
1 (7.1)
2(14.3)
3(21.4)
0
2(14.3)
8 (24.2)

Total number complications

22

28

F (1,21) = .56
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Table 3
Infant Withdrawal Course by Cocaine Exposure Status

Cocaine Neaative
N=9

Cocaine Positive
N=14

Mean (S.D.)

Mean fS.D.)

Length of Stay (d)

36.6 (25.2)

32.9(14.1)

F (1,21) = .21

Duration of Therapy (d)

30.4 (26.9)

25.8(14.1)

F (1,21) = .30

First Withdrawal Score

10.3(6.7)

10.5(4.6)

F (1,21) = .005

Age at First Withdrawal (hr)

12.7(10.0)

13.6(11.7)

F (1,21) = .03

Age at First Medication (hr)

28.2 (23.6)

53.0 (68.8)

F (1,21) = 1.07

Highest Dose Paregoric (drops/24hr)

74.9 (37.5)

82.0 (33.6)

F (1,21) = .22

# Days at Highest Dose

7.9(11.8)

3.9 (2.1)

F (1,21) = 1.54

Phenobarbital Added (%)

11.1%

14.3%

X2= .05
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Table 4
Infant Withdrawal Course by Benzodiazepine Exposure Status

Benzodiazepine
Negative
N=18

Benzodiazepine
Positive
N= 5

Mean (S.D.I

Mean fS.D.)

Methadone Dose at delivery (mg)

71.4(19.5)

101.0(14.3)

F (1,21) = 9.92**

Length of Stay (d)

29.2(13.5)

52.8 (24.7)

F (1,21) = 8.29**

Duration of Therapy (d)

21.8(13.7)

48.6 (25.0)

F (1,21) = 10.37**

First Withdrawal Score

9.8 (5.6)

12.8(4.1)

F (1,21) = 1.25

Age at First Withdrawal Score (hr)

15.0(11.4)

7.0 (5.5)

F (1,21) = 2.24

Age at First Medication (hr)

46.6 (62.2)

31.4 (26.0)

F (1,21) = .28

Highest Dose Paregoric (drops/24hr)

73.6 (35.1)

99.6 (25.3)

F (1,21) = 2.36

# Days at Highest Paregoric Dose

3.7 (3.2)

11.8(14.4)

F (1,21) = 5.36*

Phenobarbital Added, N(%)

1 (5.6%)

2 (40%)

X!= 4.09*

* p < .05
**p < .01
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